康弘药业 (002773.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

25.4x

EV/EBITDA

7.7x

Market Cap

CNY 18.87B

MomentumView details →

1D Return

−2.98%

YTD Return

−32.27%

RSI (14)

38.6

ValuationView details →

P/E (Fwd)

25.4x

EV/EBITDA

7.7x

Market Cap

CNY 18.87B

RSI (14)

38.6

MomentumView details →

1D Return

−2.98%

YTD Return

−32.27%

ProfitabilityView details →

Gross Margin

89.65%

Net Margin

24.15%

EBITDA Margin

36.53%

ROE (TTM)

11.14%

ROA (TTM)

10.48%

Asset Turnover

0.44x

GrowthView details →

Revenue YoY

−2.76%

EPS YoY

−12.32%

FCF YoY

−12.01%

Revenue CAGR 3Y

+10.60%

EPS CAGR 3Y

+8.74%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.28

EPS Surprise

833.33%

Beats (12Q)

1/12

Next Q EPS Est

CNY 0.19

Avg Surprise (4Q)

833.33%

Rev Surprise

44.68%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

12.70x

Quick Ratio

11.99x

Div Yield

3.45%

Div Rate

CNY 0.70

Div Growth 1Y

+16.67%

Financials snapshotView financials →

Revenue (TTM)

4.43B

Net Income (TTM)

1.07B

Op. CF (TTM)

1.41B

Next earningsOct 23, 2026 →

Latest newsMore news →

Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.1d ago

Kanghong Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 565 million yuan, down 22.61% year-on-year.10d ago

Similar companies

大博医疗002901.SZ 东田微301183.SZ 鸿日达301285.SZ 珠江啤酒002461.SZ 鞍钢股份000898.SZ 唯特偶301319.SZ Find similar companies →

Latest newsMore news →

Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.1d ago Kanghong Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 565 million yuan, down 22.61% year-on-year.10d ago